IP Library Granted Patent US 10,723,703
Granted Patent B2
US 10,723,703 · App. 16/193,232 · Granted Jul 28, 2020

Pyrazole compound

Inventors: Izumi Sasaki (Chuo-ku, JP); Tomohiro Toyoda (Suita, JP); Hidefumi Yoshinaga (Osaka, JP); Itaru Natsutani (Suita, JP); Yoko Takahashi (Osaka, JP)
Assignee: SUMITOMO DAINIPPON PHARMA CO., LTD.
C07D231/20C07D231/18C07D231/22C07D231/38C07D231/44C07D405/06C07D493/08
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,723,703
App. No.
16/193,232
Granted
Jul 28, 2020
Kind
B2
Abstract

The present invention relates to a novel serotonin reuptake inhibitor which also exhibits 5-HT 2C antagonistic action (antidepressive and anxiolytic effects), in particular, 5-HT 2C inverse agonistic action comprising Compound (1): or a pharmaceutically acceptable salt thereof wherein R 1 , R 2 , R 3 and R 4 are independently hydrogen or C 1-6 alkyl etc.; R 5 is C 4-7 alkyl or —(CR 8 R 9 ) r -E; R 6 , R 7 , R 8 and R 9 are independently hydrogen, fluorine or C 1-6 alkyl; A is C 6-10 aryl or heteroaryl etc.; r is 1, 2, 3 or 4; E is C 3-8 cycloalkyl or C 6-10 aryl etc.; L is oxygen, sulfur or —NR 10 —; n is 1, 2 or 3; R 10 is hydrogen or C 1-6 alkyl etc.; and X is hydrogen or halogen etc.

Claims (46)

1. A process for preparing a compound of Formula (A-4):

or a pharmaceutically acceptable salt thereof, wherein

R 1 is selected from the group consisting of a hydrogen atom, a C 1-6 alkyl group, and a C 3-8 cycloalkyl group,

R 3 and R 4 are independently selected from the group consisting of a hydrogen atom and a C 1-6 alkyl group,

R 5 is an optionally-substituted C 4-7 alkyl group or —(CR 8 R 9 ) r -E,

R 6 , R 7 , R 8 , and R 9 are independently selected from the group consisting of a hydrogen atom, a fluorine atom, and an optionally-substituted C 1-6 alkyl group,

A is an optionally-substituted C 6-10 aryl group or an optionally-substituted 5- to 10-membered heteroaryl group,

r is 1, 2, 3, or 4,

E is an optionally-substituted C 3-8 cycloalkyl group, an optionally-substituted C 4-8 cycloalkenyl group, an optionally-substituted 5- to 10-membered saturated heterocyclic group which comprises 1 to 3 heteroatoms independently selected from the group consisting of an oxygen atom and a sulfur atom as a constituent atom of the ring, an optionally-substituted C 6-10 aryl group, or an optionally-substituted 5- to 10-membered heteroaryl group,

L a is an oxygen atom or a sulfur atom, and

n is 1, 2, or 3,

which comprises the following Steps (i) and (ii):

Step (i): reacting a compound of Formula (A-1):

or a salt thereof, wherein R 1 , R 3 , R 4 , R 5 , and L a are the same as defined above and PG is a protecting group on amino groups,

with a compound of Formula (A-2):

wherein R 6 , R 7 , and n are the same as defined above and LG is a leaving group,

to obtain a compound of Formula (A-3):

or a salt thereof, wherein R 1 , R 3 , R 4 , R 5 , R 6 , R 7 , L a , n, and PG are the same as defined above, and

Step (ii): deprotecting the protecting group of the compound of Formula (A-3) to obtain the compound of Formula (A-4).

2. A process for preparing a compound of Formula (A-12):

or a pharmaceutically acceptable salt thereof, which comprises the following Steps (i) to (v):

Step (i): reacting a compound of Formula (B-7):

with a compound of Formula (B-4):

or a salt thereof,

to obtain a compound of Formula (B-8):

Step (ii): reacting the compound of Formula (B-8) with a compound of Formula (A-2):

to obtain a compound of Formula (A-13):

Step (iii): converting the compound of Formula (A-13) to a compound of Formula (B-9):

Step (iv): converting the compound of Formula (B-9) to a compound of Formula (A-10):

and

Step (v): reacting the compound of Formula (A-10) with a compound of Formula (A-11):

or a salt thereof,

to obtain the compound of Formula (A-12),

wherein

R 1 and R 2 are independently selected from the group consisting of a hydrogen atom and a C 1-6 alkyl group,

R 3 and R 4 are independently selected from the group consisting of a hydrogen atom and a methyl group,

R 5 is an optionally-substituted C 4-7 alkyl group or —(CR 8 R 9 ) r -E,

R 6 and R 7 are hydrogen atoms,

R 8 and R 9 are independently selected from the group consisting of a hydrogen atom, a fluorine atom, and an optionally-substituted C 1-6 alkyl group,

A is an optionally-substituted C 6-10 aryl group or an optionally-substituted 5- to 10-membered heteroaryl group,

r is 1 or 2,

E is an optionally-substituted C 3-8 cycloalkyl group, an optionally-substituted C 4-8 cycloalkenyl group, an optionally-substituted 5- to 10-membered saturated heterocyclic group which comprises 1 to 3 heteroatoms independently selected from the group consisting of an oxygen atom and a sulfur atom as a constituent atom of the ring, an optionally-substituted C 6-10 aryl group, or an optionally-substituted 5- to 10-membered heteroaryl group, and

n is 1,

R a is hydrogen atom or a C 1-6 alkyl group,

M 1 is hydrogen atom, an alkali metal, or an alkaline earth metal, and

LG is a leaving group.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 6, 2025
From: SUMITOMO PHARMA CO., LTD.
To: NEUROINNOVATECH APS
Reel/Frame 072810/0091 →
CHANGE OF NAME Recorded Nov 21, 2022
From: SUMITOMO DAINIPPON PHARMA CO., LTD.
To: SUMITOMO PHARMA CO., LTD.
Reel/Frame 061972/0730 →
Priority Claims (1)
JP 2010-160705 · Jul 15, 2010 · national
Continuity (6)
Continuation 15990026 · May 25, 2018
Continuation 15491130 · Apr 19, 2017
Division 14324509 · Jul 7, 2014
Division 14041246 · Sep 30, 2013
Division 13810030
Related Publication 20190084938A1 · Mar 21, 2019